RIVAL 01
Alternative Names: RIVAL-01; TAK-605; TBio-6517Latest Information Update: 04 Dec 2023
At a glance
- Originator Turnstone Biologics
- Developer Takeda; Turnstone Biologics
- Class Antibodies; Antineoplastics; Cancer vaccines; Cytokines; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fms-like tyrosine kinase 3 expression stimulants; Immunologic cytotoxicity; Interleukin-12 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 23 Jan 2023 Turnstone Biologics terminates Phase-I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Canada, South Korea and USA due to Sponsor decision (Intratumoural) (NCT04301011)
- 13 Apr 2021 Takeda anticipates the approval of RIVAL 01 for Multiple cancers in 2025/2026 (Takeda pipeline, April 2021)
- 02 Jun 2020 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in South Korea, Canada (Intratumoural) (NCT04301011)